CAS 252930-37-3

(S)-ATPO

CAS : 252930-37-3

Formule : C₁₁H₁₉N₂O₇P

Degré de pureté : 95%

Couleur et forme : Solid

Masse moléculaire : 322.2515

Ref: IN-DA00BITS

(S)-ATPO

CAS : 252930-37-3

(S)-ATPO

Formule : C₁₁H₁₉N₂O₇P

Degré de pureté : ≥98%

Masse moléculaire : 322.25

Ref: 54-BUP07331

ATPO

CAS : 252930-37-3

Formule : C₁₁H₁₉N₂O₇P

Masse moléculaire : 322.25

Ref: 7W-GL9891

(S)-ATPO

CAS : 252930-37-3

(S)-ATPO is Competitive antagonist at GluR1-4 (AMPA-preferring) receptors.

Formule : C₁₁H₁₉N₂O₇P

Degré de pureté : 98.37% - 99.41%

Couleur et forme : White Solid

Masse moléculaire : 322.25

Ref: TM-T3473

ATPO

CAS : 252930-37-3

Atovaquone is a medication used to treat chronic viral hepatitis and other conditions. It inhibits the synthesis of RNA by binding to the polymerase enzyme. This drug has been shown to be effective in treating patients with hepatitis and autoimmune diseases, such as lysis, cell lysis, and diagnosis. Atovaquone also has a role in the treatment of chronic HBV infection by inhibiting the production of viral DNA. Atovaquone is a prodrug that is converted into its active form, hydroxychloroquine (HCQ), by cytochrome P450 enzymes. HCQ is then converted into chloroquine (CQ) through further oxidation reactions. CQ can inhibit protein synthesis, leading to cell death by inhibiting the production of proteins vital for cell division.
ATPO has also been shown to have anti-inflammatory properties, which may be due to its inhibition of prostaglandin synthesis.

Formule : C₁₁H₁₉N₂O₇P

Degré de pureté : Min. 95%

Masse moléculaire : 322.25 g/mol

Ref: 3D-CKA93037